**Centers for Disease Control and Prevention** National Center for Immunization and Respiratory Diseases



## Varicella (Chickenpox) and Zoster (Shingles) Disease Varicella and Zoster Vaccines

Pink Book Webinar Series 2018

JoEllen Wolicki, BSN, RN Nurse Educator Immunization Services Division

Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences.

## Varicella Zoster Virus

- Herpes virus (DNA)
- Primary infection results in varicella (chickenpox)
- Recurrent infection results in herpes zoster (shingles)
- Short survival in environment

## **Varicella Pathogenesis**

- Respiratory transmission of virus
- Replication in nasopharynx and regional lymph nodes
- Primary viremia 4 to 6 days after infection
- Multiple tissues, including sensory ganglia, infected during viremia

## Varicella (Chickenpox) Clinical Features

- Incubation period 14 to 16 days
- Mild prodrome for 1 to 2 days (adults)
- Rash generally appears first on the head; most concentrated on the trunk
- Successive crops over several days with lesions present in several stages of development

# **Varicella Complications**

- Bacterial infection of lesions
- Hemorrhagic varicella
- CNS manifestations
- Pneumonia (primary viral or secondary bacterial)
- Congenital varicella
- Perinatal varicella
- Prevaccine era:
  - Hospitalization ~3 per 1,000 cases or 1,000/year
  - Death ~ 1 per 60,000 cases or 100/year



### Varicella with a secondary bacterial infection

## **Increased Risk of Complications of Varicella**

- Persons older than 15 years
- Infants younger than 1 year
- Immunocompromised persons
- Newborns of women with rash onset within 5 days before to 48 hours after delivery

# Varicella Epidemiology

#### **Reservoir** Human

TransmissionPerson to person – respiratory tract secretionsDirect contact with lesions

**Temporal Pattern** Peak in late winter and spring (U.S.)

**Communicability** 1 to 2 days before until lesions have formed crusts May be longer in immunocompromised

# **Herpes Zoster (Shingles)**

### Reactivation of varicella zoster virus

### Associated with:

- Aging
- Immunosuppression
- Intrauterine exposure
- Varicella disease younger than 18 months of age

## **Complications of Herpes Zoster**

 Dissemination with generalized skin eruptions and involvement of the central nervous system, lungs, liver, and pancreas

Postherpetic neuralgia (PHN)

Ophthalmic zoster

MMWR 2008;57(RR-5)



#### Zoster involving the ophthalmic division of the trigeminal nerve



Approximately 1 million episodes occur annually in the United States

- Lifetime risk of zoster estimated to be 32%
- 50% of persons living until age 85 will develop zoster

# **ACIP Recommendations: Varicella**

### Vaccines for the Prevention of Varicella (Chickenpox)

Product	ACIP Recommended Age Indications	<b>ACIP Abbreviation</b>
Varivax	12 months and older	VAR
ProQuad	12 months through 12 years	MMRV

## Varicella-Containing Vaccines:

## Varivax (Var) and ProQuad (MMRV)

#### Storage:

- Lyophilized vaccine: In the freezer between -50°C and -15°C (-58°F and +5°F)
- Diluent: At room temperature (68°F to 77°F, 20°C to 25°C) or in the refrigerator (36°F to 46°F, 2°C to 8°C)
- Preparation: Reconstitute the vaccine with the diluent supplied by the manufacturer just before administering

### Administration: Subcut injection

- Site: Fatty tissue of the anterolateral thigh or upper outer triceps of the arm
- Needle length and gauge: 5/8-inch, 23- to 25-gauge needle

## Varicella Vaccine Immunogenicity and Efficacy

### In a pre-licensure clinical trial, 2 doses of vaccine were:

- 98% effective at preventing any form of varicella
- 100% effective against severe varicella

## In post-licensure studies, 2 doses of vaccine were:

• 88% to 98% effective at preventing all varicella

## **Acceptable Evidence of Varicella Immunity**

- Written documentation of age-appropriate vaccination
- Laboratory evidence of immunity or laboratory confirmation of varicella disease
- U.S.-born before 1980\*
- Health care provider diagnosis or verification of varicella disease
- History of herpes zoster based on health care provider diagnosis

\*Birth year immunity criterion does not apply to health care personnel or pregnant women

## **Varicella Vaccination and Children**

### Routine recommendations:

- Dose 1 at 12–15 months of age
- Dose 2 at 4–6 years of age
- Minimum interval between doses is 3 months for children younger than 13 years of age

## Varicella Vaccination and Adolescents and Adults

• All persons 13 years of age and older without evidence of varicella immunity

- 2 doses separated by at least 4 weeks
- Do not repeat first dose because of extended interval between doses
- Second dose recommended for persons of any age who have only received 1 dose

## Varicella Vaccination and Health Care Personnel

- Vaccination is recommended for all susceptible health care personnel
- Prevaccination serologic screening probably cost-effective
- Postvaccination testing not necessary or recommended
- Give 2 doses, 4 weeks apart to susceptible persons

# Varicella Vaccine and Immunocompromised Persons

Single-antigen varicella vaccine may be administered to persons with isolated humoral immunodeficiency

### Consider varicella vaccination for:

- HIV-infected children with CD4 count of 15% or higher
- HIV-infected older children and adults with CD4 count of 200 or higher

## Varicella and MMRV Vaccine Contraindications

- Severe allergic reaction to a vaccine component or following a prior dose
- Pregnancy or planned pregnancy within 4 weeks\*
- Immunosuppression
- Family history of altered immunocompetence

\*ACIP off-label recommendation

MMWR 2007;56(RR-04)

General Best Practice Guidelines for Immunization: Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP) Contraindications and Precautions section <a href="http://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html">www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html</a>, accessed 08/12/2018

## **Varicella and MMRV Vaccine Precautions**

Moderate or severe acute illness with or without fever

- Recent blood product
  - Varicella or MMRV vaccines should not be administered for 3–11 months after receipt of antibody-containing blood products
- Receipt of specific antiviral drugs (acyclovir, famciclovir, or valacyclovir) 24 hours before vaccination
  - Avoid use of these antiviral drugs for 14 days after vaccination)
- Use of aspirin or aspirin-containing products

MMWR 2007;56(RR-04)\

General Best Practice Guidelines for Immunization: Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP) Contraindications and Precautions section <a href="http://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html">www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html</a>, accessed 08/12/2018

## **Varicella-Containing Vaccines Precautions**

• MMRV only: personal or family (i.e., sibling or parent) history of seizures of any etiology

These children generally should be vaccinated with separate MMR and varicella vaccines

## **Varicella Adverse Reactions**

### Local reactions (pain, erythema)

### • Varicella:

- o19% (children)
- o 24% (adolescents and adults)
- Rash: 3%–4%
- May be maculopapular rather than vesicular
- Average 5 lesions

### Systemic reactions not common

# **Adverse Reactions**

## MMRV and MMR + VAR

- Fever is more common in the 5–12 days after vaccination with MMRV (22%) than with MMR + VAR (15%)
- Data from CDC Vaccine Safety Datalink sites indicate the rate of febrile seizures following MMRV (9 per 10,000 vaccinated) was approximately 2 times higher than among those receiving MMR + VAR at the same visit (4 per 10,000 vaccinated)
- Merck postlicensure surveillance has identified a similar trend

## **MMRV Vaccine**

For the first dose of measles, mumps, rubella, and varicella vaccines at age 12–47 months, either MMR vaccine and varicella vaccine or MMRV vaccine may be used

Providers who are considering administering MMRV vaccine should discuss the benefits and risks of both vaccination options with the parents or caregivers

## **MMRV Vaccine**

### Administer MMRV:

- For the second dose of measles, mumps, rubella, and varicella vaccines at age 15 months through 12 years
- For the first dose at age 48 months or older

## **MMRV Vaccine**

 Unless the parent or caregiver expresses a preference for MMRV vaccine, CDC recommends that separate MMR vaccine and varicella vaccine should be administered for the first dose for children 12–47 months of age

# **ACIP Recommendations: Zoster**

# Vaccines for Prevention of Zoster (Shingles)

Product (ACIP Abbreviation)	Туре	ACIP Age Recommendations
Zostavax (ZVL)	Live, attenuated	60 years of age and older*
Shingrix (RZV)	Inactivated, adjuvanted	50 years of age and older

## **Zoster Vaccine: Shingrix (RZV)**

- Storage: Store vaccine AND diluent in the refrigerator between 2°C and 8°C (36°F and 46°F)
- Preparation: Reconstitute the vaccine with the diluent (adjuvant) supplied by the manufacturer just before administering
  - If not used immediately, the reconstituted vaccine may be stored in the refrigerator and use it within 6 hours of reconstitution
  - If not used,
- Schedule: 2 doses, 2 to 6 months apart
- Route: IM Injection
  - Site: Deltoid or the thigh may be used if necessary
  - Needle gauge and length: 23- to 25-gauge needle, length varies by age/weight
- RZV may be administered during the same clinical encounter as other vaccines

# **Vaccine Supply: Shingrix**

- Due to high levels of demand for GSK's Shingrix vaccine, GSK has implemented order limits and providers have experienced shipping delays
- Order limits and shipping delays will continue throughout 2018
- GSK has increased the U.S. supply available for 2018 and plans to release doses to all customer types on a consistent and predictable schedule for the rest of 2018
- Overall, the supply of Shingrix during 2018 is sufficient to support the vaccination of more patients during 2018 than were vaccinated against shingles during 2017

## **Zoster Vaccine: Zostavax (ZVL)**

#### Storage:

- Lyophilized vaccine: In the freezer between -50°C and -15°C (-58°F and +5°F)
- Diluent: At room temperature (68°F to 77°F, 20°C to 25°C) or in the refrigerator (36°F to 46°F, 2°C to 8°C)
- Preparation: Reconstitute the vaccine with the diluent supplied by the manufacturer just before administering
- Schedule: 1 dose
- Administration: Subcut injection
  - Site: Fatty tissue of the upper outer triceps of the arm
  - Needle length and gauge: 5/8-inch, 23- to 25-gauge needle

# Live Zoster Vaccine (ZVL) Efficacy

Vaccine recipients 60 to 80 years of age had 51% fewer episodes of zoster


- Efficacy declines with increasing age
- Significantly reduces the risk of postherpetic neuralgia
- Reduces the risk of zoster 69.8% in persons 50 through 59 years of age

## **RZV Vaccine Efficacy**

### Efficacy for the prevention of zoster:

- 96.6% in adults age 50 to 59 years
- 97.4% in adults age 60 to 69 years
- 91.3% in adults age 70 years and older
- The efficacy for the prevention of postherpetic neuralgia (PHN) was:
  - 91.2% in adults age 50 years and older
  - 88.8% in adults age 70 years and older

#### Vaccine Efficacy and Effectiveness against HZ for HZ/su and ZVL, by Age Group, During the First 4<sup>‡</sup> Years Following Vaccination



HZ/su (ZOE 50/70)<sup>^</sup> ZVL (RCTs<sup>\*</sup>) ZVL (Baxter 2017) ZVL (Izurieta 2017)

<sup>+</sup> Median follow-up may be less than 3 yrs: Schmader 2012= 1.3 yrs ^ZOE 50/70= 50-59 and 60-69yr: Lal 2015, 70+yrs: Cunningham 2016 \*RCTs= 50-59 yrs: Schmader 2012, 60-69 and 70+ yrs: Oxman 2005,

## **ACIP Zoster Immunization Recommendations**

# Administer 2 doses of Shingrix to immunocompetent persons 50 years of age and older

Regardless of previous history of:

Vaccination with varicella-containing vaccines–Varivax or Zostavax
 Zoster disease

# Shingrix is preferred to Zostavax for persons 60 years and older

 Separate varicella-containing vaccines and Shingrix by at least 8 weeks

### **Zoster Vaccination:**

Patients Who Do Not Report A Prior Episode of Varicella

- When vaccinating adults 50 years of age and older, there is no need to:
  - Screen for a history of varicella (chickenpox) infection OR
  - Conduct laboratory testing for serologic evidence of prior varicella infection
- More than 99% of adults age 50 years and older worldwide have been exposed to varicella zoster virus
- ACIP considers people born in the United States prior to 1980 immune to varicella

## **Zoster Vaccine and Serology**

#### If tested and varicella-negative:

- Administer 2 doses of single-antigen varicella vaccine (Varivax) separated by at least 4 weeks
- Followed by 2 doses of RZV, separated by 2–6 months
   Separate the 2<sup>nd</sup> (last) dose of varicella and 1<sup>st</sup> dose of RZV by at least 8 weeks

## **RZV Contraindications and Precautions**

- History of severe allergic reaction, such as anaphylaxis, to any component of a vaccine or after a previous dose of Shingrix
- Moderate to severe illness, including an acute episode of herpes zoster
  - Shingrix is not a treatment for herpes zoster or postherpetic neuralgia (PHN)
- Shingrix has not been studied in pregnant women or women who are breastfeeding. Providers should consider delaying Shingrix vaccination for these women

## **RZV and Immunosuppressive Therapy**

#### Administer RZV to persons:

- Taking low-dose immunosuppressive therapy (e.g., <20 mg/day of prednisone or equivalent or using inhaled or topical steroids)
- Anticipating immunosuppression
- Who have recovered from an immunocompromising illness
- ACIP has not yet made recommendations regarding use RZV in these patients
  - Persons on moderate to high doses of immunosuppressive therapy were excluded from RZV efficacy studies

## **Zostavax (ZVL) Contraindications**

- History of a life-threatening or severe allergic reaction to gelatin, the antibiotic neomycin, or any other component of ZVL
- A weakened immune system because of:
  - HIV/AIDS or another disease that affects the immune system
  - Treatment with drugs that affect the immune system
  - Cancer treatment such as radiation or chemotherapy
  - Cancer affecting the bone marrow or lymphatic system, such as leukemia or lymphoma
- Women who are or might be pregnant
  - Women should not become pregnant until at least 4 weeks\* after getting ZVL

## **Zostavax (ZVL) Vaccine Precautions**

- Moderate or severe acute illness
- Current treatment with an antiviral drug active against herpes viruses
  - Discontinue at least 24 hours before administration of zoster vaccine
  - Should not be taken for at least 14 days after vaccination

Recent receipt of a blood product is NOT a precaution

## **Zostavax (ZVL) Adverse Reactions**

Local reactions–34% (pain, erythema)

#### No increased risk of fever

#### No serious adverse reactions identified

## **RZV (Shingrix) Adverse Reactions**

Local reactions	49%
Local reactions–Grade 3	9.4%
Systemic reactions (headache, malaise, fatigue) Systemic reactions (headache, malaise, fatigue)–Grade 3	45–78% 11%


## **Adverse Reactions after Shingrix**

#### Educate patients regarding:

- Potential adverse reactions, including injection site and systemic reactions
- The need for a second dose-even if s/he has an adverse reaction
- Offer comfort measures and strategies



## Vaccine Information Statements



				_			
VACCINE	INFORMATION STAT	TEMENT		1			
Zoster (Shi d to Know	ngles) Vaccine	e, RZV:	Many libecine Information Statements are available in Spanish and other Tangoagen. See www.lemaniza.org/vib Rojes de información sobre vacutas entim disponibles en español y en machos otros disponibles en español y en machos otros disponibles en español y en machos otros				
cinated?		hingles va		1			
s zoster, or just zoste a blisters. Shingles is the same virus that chickenpos, the vir shingles later in life	r) is a caused Recombin causes 2017 for it as stays was more can also re	ant shingles vac he prevention of than 90% effect educe the likelih	cine was approved by FDA in shingles. In clinical trials, it we in preventing shingles. It ood of PHN.				
m another person. I I chickenpox (or chi ox from someone w	ckenpox adults 50 ith This vacua already go	and older. ne is also recom tten the live shi	apart, are recommended for mended for people who have ngles vaccine (Zostavax). Ther	e			
ears on one side of t 4 weeks. Its main a	he face or is no live v	rirus in this vac	ine.	÷			
Other symptoms c upset stomach. Ve							
i to pneumonia, h inflammation (enc	Varicella What You N					Many Vaccine information Statements are available in Spanish and other languages. See www.lmmanize.org/vis Hojas de información sobre vacunas están	
		leed to	KIIOW			disponibles en español y en muchos otros Idiomas. Visite www.immunize.org/vis	
	<b>1</b> Why get	vaccinat	ed?	and at age or	least 28 days after th older.	he first dose for those 13 years of	
	Varicella (also called cl disease. It is caused by is usually mild, but it ca	the varicella zo	ster virus. Chickenpox		re no known risks t ne time as other vac	to getting chickenpox vaccine at ccines.	
ere pain can conti ed up. This long-b	months of age, adolesco people with weakened Chickenpox causes an week. It can also cause:	ents, adults, pre immune systen itchy rash that	gnant women, and 15.	cont MM	ains both chicken RV is an option for	n vaccine called <b>MMRV</b> that npox and MMR vaccines. r some children 12 months ge. There is a separate	
algia (PHN). en in people 50 yes	<ul> <li>fever</li> <li>tiredness</li> <li>loss of appetite</li> </ul>					tatement for MMRV. Your an give you more information.	
scople, and the ris nmon in people w	<ul> <li>headache</li> </ul>				Some need	ple should not get	
d because of a dis as steroids or cher	<ul> <li>More serious complications</li> </ul>		le:	3	this vaccir	ne	
ear in the United	<ul> <li>infection of the lungs</li> <li>inflammation of bloo</li> </ul>					if the person getting the vaccine:	
<ul> <li>swelling of the brain and/or spinal cord coverings (encephalitis or meningitis)</li> </ul>			<ul> <li>Has any severe, life-threatening allergies. A person who has ever had a life-threatening allergic reaction after a dose of chickenpox vaccine, or has a severe allergy to any part</li> </ul>				
	<ul> <li>blood stream, bone, or joint infectiona</li> <li>Some people gris os ack that they need to be hospitalized. It doesn't happen often, but people can die from chickenpox.</li> <li>Before varacella vaccine, aimot everyone in the United States got chickenpox, an average of 4 million people each year.</li> </ul>			of this vaccine, may be advised not to be vaccinated. Ask your health care provider if you want information about vaccine components. • Is pregnant, or thinks she might be pregnant. Pregnant women should wait to get chickenpox vaccine until after			
	Children who get chick 6 days of school or chil		miss at least 5 or	they pregr vacci	ant for at least 1 m	ant. Women should avoid getting onth after getting chickenpox	
	Some people who get c shingles (also known a	s herpes zoster)	years later.	as ca	ncer or HIV/AIDS)	ne system due to disease (such or medical treatments (such as	
	Chickenpox can spread anyone who has not ha chickenpox vaccine.			• Has a	parent, brother, o	py, steroids, or chemotherapy). or sister with a history of immune	
		pox vacc	ino	• Is tal		ch as aspirin). People should	
	Children 12 months th	•	)	avoid vacci		or 6 weeks after getting varicella	
	2 doses of chickenpox v • First dose: 12 through • Second dose: 4 through	vaccine, usually h 15 months of	: age	bloo	l products. You mig	d transfusion or received other ght be advised to postpone for 3 months or more.	
	People 13 years of age of when they were younge should get 2 doses at le	er, and have ne	er had chickenpox,	• Has t	uberculosis.		

A person who previously received only one dose of chickenpox vaccine should receive a second dose to complete the series. The second dose should be given at least 3 months after the first dose for those younger than 13 years

#### There is a VIS for:

- ZVL (Zostavax)
- RZV (Shingrix)
- Var (Varicella)
- MMRV (ProQuad)

Give the parent or patient the appropriate VIS for the product that will be administered

## **Real-Life Shingrix Administration Errors**

- Notes from the Field: Vaccine Administration Errors Involving Recombinant Zoster Vaccine
- 13 (8%) of the 155 reports to VAERS regarding Shingrix documented a vaccine administration error

Notes from the Field	
Vaccine Administration Errors Involving Recombinant Zoster Vaccine — United States, 2017-2018 Tom T. Shimabukuro, MD <sup>1</sup> ; Elaine R. Miller, MPH <sup>1</sup> ; Raymond A. Strikas, MD <sup>2</sup> ; Beth F. Hibbs, MPH <sup>1</sup> ; Kathleen Dooling, MD <sup>3</sup> ; Ravi Goud, MD <sup>4</sup> ; Maria V. Cano, MD <sup>1</sup> Two vaccines for the prevention of herpes zoster (shingles) are licensed for use in the United States and recommended by the Advisory Committee on Immunization Practices (ACIP). Zoster vaccine live (ZVL; Zostavax, Merck), licensed in 2006,* is a live attenuated virus vaccine administered as a single subcutane- ous (SQ) dose. Although the Food and Drug Administration (FDA) approved ZVL for adults aged ≥50 years, ACIP recom- mends ZVL for immunocompetent adults aged ≥60 years ( <i>1</i> ). Recombinant zoster vaccine (RZV; Shingrix, GlaxoSmithKline), licensed October 2017, <sup>†</sup> is also approved by the FDA for adults	also described vaccination of a person aged 48 years (inappro- priate age), and two described patients receiving the vaccine information statement for ZVL instead of RZV and not being instructed to return for the second RZV dose. The remaining four reports included 1) administration of RZV instead of the intended varicella (Varivax) vaccine to a person of unreportec age, 2) administration of RZV after incorrect frozen storage 3) administration of RZV to a person aged 39 years, and 4) administration of only the adjuvant component withou reconstitution with the vaccine antigen. Vaccine administra- tion errors occurred in a pharmacy (nine reports), a health care provider's office (two), and unknown sites (two). CDC also received 13 public inquiries concerning RZV administration errors or questions asked to avoid errors. Topics included SQ administration (five), reconstitution (five), incorrect interva or schedule (two), and administration of previously frozer vaccine (one).

## **Shingrix Vaccine Administration Errors**

- Vaccine administration errors reported to VAERS include:
  - Wrong route: Subcut route rather than the IM
  - Wrong age: Administered to persons less than 50 years of age
  - Wrong vaccine: Shingrix instead of varicella (Varivax) vaccine
  - Improper storage: Administered after frozen storage
  - Wrong preparation: Administered the adjuvanted diluent only
  - Wrong schedule: Interval violations between doses of Shingrix or a previous dose of varicella-containing vaccine

#### Other errors we have heard about:

- Staff unaware of the need for a second dose
- Staff thinks Zostavax can count toward completing the 2-dose Shingrix series

## Varicella and Zoster Vaccine Resources and References

Resources and references are available on the webinar web page

#### Varicella and Zoster Vaccines Resources and References **2018 PINK BOOK WEBINAR SERIES** ACIP recommendations Current ACIP varicella vaccine recommendations www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/varicella.html Current ACIP MMRV recommendations www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mmrv.html Current ACIP zoster vaccine recommendations www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/shingles.html ACIP Update on the use of herpes zoster vaccine www.cdc.gov/mmwr/volumes/67/wr/mm6703a5.html Manufacturer's vaccine package inserts (PI) VAR (Varivax), Merck & Co., Inc. www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm200582.htm MMRV (ProQuad), Merck & Co., Inc. www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094051.htm RZV (Shingrix), GlaxoSmithKline, Biologicals www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm581605.pdf ZVL (Zostayax) Merck & Co., Inc. www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm132831.pdf Schedule 2018 Recommended immunization schedule for persons aged 18 years and younger www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html 2018 Recommended immunization schedule for adults 19 years and older www.cdc.gov/vaccines/schedules/hcp/adult.html Disease Chickenpox disease webpage www.cdc.gov/chickenpox/about/ Information you need to know www.vaccineinformation.org/chickenpox/ Shingles (Herpes Zoster) www.cdc.gov/shingles/hcp/index.html Information for health care personnel Epidemiology and Prevention of Vaccine-Preventable Diseases: Varicella chapter \_www.cdc.gov/vaccines/pubs/pinkbook/chapters.html Ask the Experts: varicella questions <u>www.immunize.org/askexperts/experts var.asp</u> Ask the Experts: zoster questions www.immunize.org/askexperts/experts zos.asp CDC Zoster Fact Sheet www.cdc.gov/shingles/downloads/shingles-factsheet-hcp.pdf MMR & varicella vaccines or MMRV vaccine: discussing options with parents www.cdc.gov/vaccines/vpd/mmr/hcp/vacopt-factsheet-hcp.html You Call the Shots: Varicella www.cdc.gov/vaccines/ed/youcalltheshots.html You Call the Shots: Zoster www.cdc.gov/vaccines/ed/youcalltheshots.html You call the Shots: Zoster job aid www.cdc.gov/vaccines/hcp/infographics/you-call-the-shots-intramuscular-shingrix-vaccination.html Varicella information www.immunize.org/varicella/ Zoster information www.immunize.org/zoster/